24,003 results match your criteria Chronic Lymphocytic Leukemia


Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

J Clin Oncol 2019 Apr 17:JCO1801460. Epub 2019 Apr 17.

18 Ulm University, Ulm, Germany.

Purpose: A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01460DOI Listing

Multiple Faces of Chronic Lymphocytic Leukaemia: A Patient with Renal, Cardiac, and Skeletal Complications.

Case Rep Nephrol 2019 12;2019:5390235. Epub 2019 Mar 12.

Department of Renal Medicine, Norfolk and Norwich University Hospital, Norwich, UK.

We describe a patient who had chronic lymphocytic leukaemia (CLL) Binet stage A at presentation with further evidence of disease at multiple sites but who initially required no treatment. However, several years later, her peripheral blood lymphocyte count started to increase, and soon after that she suffered an acute myocardial infarct (in the absence of coronary atheroma) together with proteinuric renal failure due to membranoproliferative glomerulonephritis. Her renal function improved markedly following anti-CLL chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/5390235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434293PMC

Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event.

J Eur Acad Dermatol Venereol 2019 Apr 16. Epub 2019 Apr 16.

Department of Dermatology, Catholic University of the Sacred Heart, Fondazione Policlinico A. Gemelli - IRCCS, Rome.

Chronic lymphocytic leukaemia (CLL) is the most common adult-onset lymphoproliferative disorder, characterised by the accumulation of monoclonal neoplastic B lymphocytes. Patients are usually asymptomatic and diagnosis is often incidental. Poor prognosis is associated to cytogenetic alterations such as TP53 mutation or deletion(17p), and such patients show no response or rapid disease progression with standard rituximab-based combination chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15632DOI Listing

Detection of a deletion at 22q11 locus involving ZNF280A/ZNF280B/PRAME/GGTLC2 in B-cell malignancies: simply a consequence of an immunoglobulin lambda light chain rearrangement.

Br J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Department of Internal Medicine, Haematology and Oncology, University Hospital Brno and Faculty of Medicine MU, Brno, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15922DOI Listing

Quantitative Cytologic Descriptors to Differentiate CLL, Sézary, Granular, and Villous Lymphocytes Through Image Analysis.

Am J Clin Pathol 2019 Apr 16. Epub 2019 Apr 16.

Department of Mathematics, Barcelona Est Engineering School, Technical University of Catalonia, Barcelona, Spain.

Objectives: We aimed to find descriptors to identify chronic lymphocytic leukemia (CLL), Sézary, granular, and villous lymphocytes among normal and abnormal lymphocytes in peripheral blood.

Methods: Image analysis was applied to 768 images from 15 different types of lymphoid cells and monocytes to determine four discriminant descriptors. For each descriptor, numerical scales were obtained using 627 images from 79 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqz025DOI Listing

Clinical Aspects, Immunophenotypic Analysis and Survival Rate of Chronic Lymphocytic Leukaemia Patients in Erbil City, Iraq.

Authors:
Kawa M Hasan

Sultan Qaboos Univ Med J 2018 Nov 28;18(4):e461-e467. Epub 2019 Mar 28.

Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq.

Objectives: Chronic lymphocytic leukaemia (CLL) is characterised by an accumulation of clonal B cells in the blood, bone marrow and lymphatic tissue. This study aimed to evaluate the clinical and immunophenotypic characteristics and survival rate of CLL patients.

Methods: This retrospective study was conducted at the Nanakaly Hospital for Blood Diseases & Oncology in Erbil, Iraq, between January 2011 and December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18295/squmj.2018.18.04.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443287PMC
November 2018

Leukemia Cutis: A Rare Initial Presentation of Chronic Lymphocytic Leukemia.

Indian J Hematol Blood Transfus 2019 Apr 6;35(2):367-368. Epub 2018 Dec 6.

3Department of Laboratory Oncology, AIIMS, New Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-1057-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439032PMC

Prognostic Significance of Serum BAFF, APRIL, TACI and BCMA Levels in Chronic Lymphocytic Leukemia.

Indian J Hematol Blood Transfus 2019 Apr 10;35(2):265-271. Epub 2018 Oct 10.

2Department of Hematology, School of Medicine, Gazi University, Ankara, Turkey.

As chronic lymphocytic leukemia (CLL) has a variable disease course, novel prognostic markers and risk assessment models are being developed in order to identify high-risk patients who may need early treatment. The two tumor necrosis factor family proteins BAFF and APRIL and their receptors BAFF-R, TACI and BCMA are considered to play a critical role in the survival of normal B cells. In order to highlight the pathophysiological role of this complicated biological network, we aimed to analyze the potential prognostic effects of BAFF, APRIL, TACI and BCMA in CLL patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12288-018-1029-7
Publisher Site
http://dx.doi.org/10.1007/s12288-018-1029-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439071PMC
April 2019
1 Read

Reduced Dose Ibrutinib Due to Financial Toxicity in CLL.

Indian J Hematol Blood Transfus 2019 Apr 8;35(2):260-264. Epub 2018 Sep 8.

Clinical Hematology, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Ibrutinib is the only approved novel agent that is available for the treatment of relapsed-refractory and treatment-naive chronic lymphocytic leukemia patients with deletion 17p or TP53 mutation in India. The cost of ibrutinib is still prohibitive for most Indian CLL patients. We report here for the first time dose reductions due to the patient preference of financial toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12288-018-1011-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439022PMC

Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.

J Immunol 2019 Apr 15. Epub 2019 Apr 15.

The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY 11030;

Clonal expansion of B cell chronic lymphocytic leukemia (B-CLL) occurs within lymphoid tissue pseudofollicles. IL-15, a stromal cell-associated cytokine found within spleens and lymph nodes of B-CLL patients, significantly boosts in vitro cycling of blood-derived B-CLL cells following CpG DNA priming. Both IL-15 and CpG DNA are elevated in microbe-draining lymphatic tissues, and unraveling the basis for IL-15-driven B-CLL growth could illuminate new therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1801142DOI Listing

Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.

Blood Adv 2019 Apr;3(8):1255-1266

The James Comprehensive Cancer Center and.

Prostate apoptosis response 4 (Par-4) is a tumor suppressor that prevents proliferation and induces cell death in several solid tumors. However, its role in B-cell malignancies has not been elucidated. To describe the role of Par-4 in chronic lymphocytic leukemia (CLL) pathogenesis, we developed a B-cell-specific human Par-4-overexpressing mouse model of CLL using the TCL1 leukemia model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018025973DOI Listing

Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.

Kidney Int 2019 Mar 15. Epub 2019 Mar 15.

Department of Nephrology and Renal Transplantation, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France; CNRS UMR 7276, INSERM UMR 1262, Université de Limoges, Limoges, France; INSERM CIC 1402, Centre Hospitalier Universitaire, Poitiers, France.

The clinicopathological characteristics of kidney infiltration in B-cell lymphoproliferative disorders remain poorly described. We retrospectively studied 52 adults with biopsy-proven malignant B-cell kidney infiltration, including Waldenström's macroglobulinemia (n=21), chronic lymphocytic leukemia (n=11), diffuse large B-cell lymphoma (DLBCL) (n=8), other lymphoma (n=11), and multiple myeloma (n=1). Kidney disease varied according to the underlying lymphoproliferative disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2019.01.027DOI Listing

New Quinoline-Based Heterocycles as Anticancer Agents Targeting Bcl-2.

Molecules 2019 Apr 2;24(7). Epub 2019 Apr 2.

School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, Wales CF10 3NB, UK.

The Bcl-2 protein has been studied as an anticancer drug target in recent years, due to its gatekeeper role in resisting programmed cancer cell death (apoptosis), and the design of BH3 domain mimetics has led to the clinical approval of Venetoclax (ABT-199) for the treatment of chronic lymphocytic leukaemia. In this work we extend our previous studies on the discovery of indole-based heterocycles as Bcl-2 inhibitors, to the identification of quinolin-4-yl based oxadiazole and triazole analogues. Target compounds were readily synthesized via a common aryl-substituted quinolin-4-carbonyl--arylhydrazine-1-carbothioamide () intermediate, through simple variation of the basic cyclisation conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24071274DOI Listing

Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway.

Cancer Epidemiol 2019 Apr 12;60:128-133. Epub 2019 Apr 12.

Department of Haematology, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; K.G. Jebsen Centre for B-Cell malignancies, University of Oslo, Oslo, Norway.

Background: Transformation to aggressive lymphoma (Richter syndrome, RS) occurs in a substantial subset of patients who must discontinue targeted therapy for chronic lymphocytic leukemia (CLL). RS has an extremely poor prognosis.

Methods: Using the nation-wide database of The Cancer Registry of Norway of 7664 CLL patients registered between 1953-2012, we identified 107 patients experiencing RS. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18777821183046
Publisher Site
http://dx.doi.org/10.1016/j.canep.2019.04.002DOI Listing
April 2019
1 Read

Bone Marrow Aspirate Clot: A Useful Technique in Diagnosis and Follow-Up of Hematological Disorders.

Case Rep Hematol 2019 10;2019:7590948. Epub 2019 Mar 10.

São Paulo State University (UNESP), Medical School of Botucatu, Department of Pathology, Botucatu, SP, Brazil.

Bone marrow biopsy is a diagnostic tool largely used in the evaluation of a broad number of disorders that could affect the hematopoietic system. Differently, bone marrow aspirate clot technique is rarely performed even though it has been described in literature. Here, we highlight the utility of the bone marrow aspirate clot, exemplifying through the discussion of three clinical cases in which this technique was used for diagnosis and follow-up purposes: megaloblastic hemopathy, multiple myeloma, and chronic lymphocytic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7590948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431525PMC

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.

Cancer Med 2019 Apr 14. Epub 2019 Apr 14.

William Jennings Bryan Dorn Veterans Affairs Medical Center, Columbia, South Carolina.

Chronic lymphocytic leukemia (CLL) patients are at increased risk for major hemorrhage (MH). We examined incidence of and risk factors for MH in CLL patients before introduction of newer CLL therapies such as ibrutinib, which includes bleeding risk. This study included 24 198 CLL patients treated in the VA system before FDA approval of ibrutinib as CLL therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2134DOI Listing

Unilateral granuloma annulare in association with pyoderma gangrenosum and chronic lymphocytic leukemia.

Dermatol Online J 2019 Mar 15;25(3). Epub 2019 Mar 15.

Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.

Granuloma annulare (GA) is a fairly common inflammatory skin condition with a range of clinical subtypes. We describe an unusual case of unilateral GA confined to the thigh on a previously amputated limb. A man in his 80s with a past medical history of below-knee amputation of the left leg owing to severe leg ulcers from pyoderma gangrenosum, chronic lymphocytic leukemia, and dyslipidemia developed a slowly spreading eruption on the distal stump spreading proximally. Read More

View Article

Download full-text PDF

Source

Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults.

J Am Acad Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Assistance Publique-Hôpitaux de Paris, Département de Dermatologie, Hôpital Saint-Louis, Paris, France; Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. Electronic address:

Background: Paraneoplastic pemphigus (PNP) occurs more often in patients with hematologic malignancies (HMs) than in patients with solid cancer. Lung bronchiolitis obliterans (BO) is a severe complication of PNP.

Objective: To determine the precise clinical and biologic features of HM-associated PNP and identify factors associated with mortality and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.043DOI Listing

Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.

Br J Haematol 2019 Apr 13. Epub 2019 Apr 13.

Tel Aviv University, Tel Aviv.

The question of which chemotherapy induction provides the best results for indolent lymphoma patients is yet unanswered. Different regimens have been compared, none of which has been shown to improve overall survival. The use of bendamustine is growing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15901DOI Listing
April 2019
2 Reads

IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.

Cell Death Dis 2019 Apr 11;10(4):320. Epub 2019 Apr 11.

Department of Experimental and Clinical Medicine, University Magna Græcia of Catanzaro, Catanzaro, 88100, Italy.

Increasing evidence supports the involvement of IBTK in cell survival and tumor growth. Previously, we have shown that IBTK RNA interference affects the wide genome expression and RNA splicing in cell-type specific manner. Further, the expression of IBTK gene progressively increases from indolent to aggressive stage of chronic lymphocytic leukemia and decreases in disease remission after therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1557-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459904PMC
April 2019
1 Read

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.

Haematologica 2019 Apr 11. Epub 2019 Apr 11.

University Hospital Brno and Faculty of Medicine, Masaryk University;

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is therefore of critical importance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203430DOI Listing
April 2019
1 Read

Red blood cell utilization and transfusion triggers in patients diagnosed with chronic lymphocytic leukaemia in Iceland 2003-2016.

Vox Sang 2019 Apr 10. Epub 2019 Apr 10.

Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

Background And Objectives: Revised Icelandic guidelines proposed a restrictive haemoglobin (Hb) threshold of 70 g/l for red blood cell (RBC) transfusions in general, but 100 g/l for malignancies/bone marrow suppression. Chronic lymphocytic leukaemia (CLL) is frequently complicated by anaemia. The objective was to investigate RBC transfusion practices in CLL. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/vox.12775
Publisher Site
http://dx.doi.org/10.1111/vox.12775DOI Listing
April 2019
4 Reads

Venetoclax in the treatment of chronic lymphocytic leukemia.

Expert Opin Drug Metab Toxicol 2019 Apr 10. Epub 2019 Apr 10.

a Department of Hematology , Medical University of Lodz , 93-510 Lodz, Ciolkowskiego 2, Poland.

Introduction: Venetoclax, an antagonist of BCL-2 protein plays an important role in the pathogenesis of chronic lymphocytic leukemia (CLL). It has been approved by the FDA for the treatment of relapsed/refractory CLL with del17p, and by the EMA for patients with del17p/TP53 mutation who have failed a BCR inhibitor, or in patients without those aberrations who have failed previous therapy, regardless of their genetic/molecular profile. Venetoclax in combination with rituximab has been also approved for the treatment of CLL after at least 1 prior therapy, regardless of del17p. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17425255.2019.1606211DOI Listing
April 2019
1 Read

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Blood Adv 2019 Apr;3(7):1167-1174

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

PI3 kinase (PI3K) activity is critical for survival of neoplastic B cells in patients with chronic lymphocytic leukemia (CLL). Blockade of PI3K signaling with idelalisib is effective for the treatment of relapsed CLL in combination with the anti-CD20 antibody ofatumumab. In this single-arm, open-label, nonrandomized phase 2 study, we investigated the efficacy and safety of idelalisib with ofatumumab in 27 patients with treatment-naïve CLL in need of therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018030221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457234PMC
April 2019
3 Reads

Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.

Heart Rhythm 2019 Apr 5. Epub 2019 Apr 5.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China. Electronic address:

Background: Ibrutinib is a novel anti-tumor drug that targets Bruton's tyrosine kinase (BTK) for the treatment of chronic lymphocytic leukemia. Atrial fibrillation (AF) occurs in 5-9% of patients during treatment, but the underlying mechanisms remain unclear.

Objective: In the present study, we developed a mouse model of ibrutinib induced AF and investigated its' proarrhythmic mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hrthm.2019.04.008DOI Listing
April 2019
1 Read

Transcriptomics-based validation of the relatedness of heterogeneous nuclear ribonucleoproteins to chronic lymphocytic leukemia as potential biomarkers of the disease aggressiveness.

Saudi Med J 2019 Apr;40(4):328-338

Department of Medical Laboratories Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah, Kingdom of Saudi Arabia. E-mail.

Objectives: To use independent transcriptomics data sets of cancer patients with prognostic information from public repositories to validate the relevance of our previously described chronic lymphocytic leukemia (CLL)-related proteins at the level of transcription (mRNA) to the prognosis of CLL.  Methods: This is a validation study that was conducted at Majmaah University, Kingdom of Saudi Arabia between January-2017 and July-2018. Two independent data sets of CLL transcriptomics from Gene Expression Omnibus (GEO) with time-to-first treatment (TTFT) data (GSE39671; 130 patients) and information about overall survival (OS) (GSE22762; 107 patients) were used for the validation analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15537/smj.2019.4.23380DOI Listing
April 2019
2 Reads

Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia.

Saudi Med J 2019 Apr;40(4):317-327

Department of Medical Laboratories Sciences, Faculty of Applied Medical Sciences, Majmaah University, Majmaah, Kingdom of Saudi Arabia. E-mail.

Chronic lymphocytic leukemia (CLL) is an incurable malignant disease of B-lymphocytes characterized by drastically heterogeneous clinical courses. Proteomics is an advanced approach that allows a global profiling of protein expression, providing a valuable chance for the discovery of disease-related proteins. In the last 2 decades, several proteomics studies were conducted on CLL to identify aberrant protein expression underpinning the malignant transformation and progression of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15537/smj.2019.4.23598DOI Listing
April 2019
1 Read

Neglected players: Tumor associated neutrophils involvement in chronic lymphocytic leukemia progression.

Oncotarget 2019 Mar 8;10(20):1862-1863. Epub 2019 Mar 8.

Laboratorio de Inmunología Oncológica, IMEX-CONICET, Ciudad de Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26716DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443013PMC
March 2019
1 Read

Treatment decision-making in chronic lymphocytic leukaemia: Key factors for healthcare professionals. PRELIC study.

J Geriatr Oncol 2019 Apr 3. Epub 2019 Apr 3.

Outcomes'10, Castellón, Spain; Departamento de Medicina, Universitat Jaume I, Castellón, Spain.

Objective: To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse, condition that mainly afflicts older adults.

Methods: A discrete choice experiment (DCE) was conducted among haematologists and hospital pharmacists. A literature review and a focus group informed the DCE design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.03.010DOI Listing
April 2019
3 Reads

Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.

Clin Pharmacokinet 2019 Apr 5. Epub 2019 Apr 5.

AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.

Introduction: Venetoclax is a selective B cell lymphoma-2 inhibitor. It is approved for treatment of chronic lymphocytic leukemia and is being investigated for other hematological malignancies. Venetoclax is predominantly eliminated by the liver; therefore, there is a need to investigate the effect of hepatic insufficiency on venetoclax pharmacokinetics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-019-00746-4DOI Listing
April 2019
3 Reads

LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy.

Cancer Cell Int 2019 21;19:67. Epub 2019 Mar 21.

1Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.

Background: Low molecular weight protein tyrosine phosphatase (LMW-PTP) is overexpressed in different cancer types and its expression is related to more aggressive disease, reduced survival rate and drug resistance. Morin is a natural polyphenol which negatively modulates, among others, the activity of LMW-PTP, leading to the potentiation of the effects of different antitumoral drugs, representing a potential beneficial treatment against cancer.

Methods: LMW-PTP levels were measured by immunoblot analysis both in CLL cells from patients and in chronic lymphocytic leukemia (CLL)-derived Mec-1 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0786-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429822PMC
March 2019
2 Reads

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Clin Lymphoma Myeloma Leuk 2019 Mar 11. Epub 2019 Mar 11.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA. Electronic address:

Background: Patients with chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy are at increased risk of developing therapy-related (t-) myelodysplastic syndrome (MDS). It is unclear whether antecedent CLL adds prognostic value to the revised International Prognostic Scoring System (IPSS-R) for MDS. We performed a retrospective analysis to evaluate the significance of a previous CLL diagnosis as an independent adverse prognostic factor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.003DOI Listing
March 2019
1 Read

Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia.

Hematol Oncol 2019 Apr 4. Epub 2019 Apr 4.

Department of Biochemistry and Molecular Biology, National and Kapodistrian University of Athens, GR, Athens, Greece.

tRNA-derived fragments (tRFs) are 16-28 nucleotide fragments, which occur by specific cleavage of tRNA molecules. i-tRF-GlyGCC is an internal tRF, originating from the tRNAs bearing the Glycine anticodon "GCC". Other tRFs generated from tRNA have proved to be associated with various cancer types. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/hon.2616
Publisher Site
http://dx.doi.org/10.1002/hon.2616DOI Listing
April 2019
2 Reads

Chronic lymphocytic leukaemia: the role of T cells in a B cell disease.

Br J Haematol 2019 Apr 3. Epub 2019 Apr 3.

Section of Haematology, Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.

Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any) in disease progression remains unclear and has not been directly studied. This has changed with the advent of new therapies, such as chimeric antigen receptor-T cells, which actively use retargeted patient-derived T cells as "living drugs" for CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15918DOI Listing
April 2019
1 Read

Efficiency and Health Economic Evaluations of BD OneFlow™ Flow Cytometry Reagents for Diagnosing Chronic Lymphoid Leukemia.

Cytometry B Clin Cytom 2019 Apr 2. Epub 2019 Apr 2.

Newcastle Upon Tyne Hospitals NHS Foundation Trust, Cancer Services/Clinical Haematology, Newcastle upon Tyne, UK.

Reason For The Study: To standardize the use of flow cytometry for classifying hematological malignancies and make the results reliable and reproducible across laboratories, the EuroFlow™ Consortium published a comprehensive specification of antibody-fluorochrome conjugates, standard protocols, and algorithms for analysis. The BD OneFlow™ system builds on, and further standardizes, the EuroFlow protocols. We aimed to assess the effects on safety, efficiency, and costs for laboratories of adopting the BD OneFlow reagent tubes (LST and B-CLPD T1) for diagnosing chronic lymphocytic leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21779DOI Listing
April 2019
1 Read

Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy.

Case Rep Pathol 2019 3;2019:4915086. Epub 2019 Mar 3.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries with an incidence of 3-5 cases per 100,000 persons. Most patients follow an indolent clinical course with eventual progression and need for therapy. In contrast, T-prolymphocytic leukemia (T-PLL) is a rare type of T-cell leukemia with most patients having an aggressive clinical course and a dismal prognosis. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/cripa/2019/4915086/
Publisher Site
http://dx.doi.org/10.1155/2019/4915086DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420994PMC
March 2019
4 Reads

Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL).

Clin Cancer Res 2019 Apr 2. Epub 2019 Apr 2.

Cancer Biology, Mayo Clinic

Purpose: CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 monoclonal antibody). The clinical importance of CD38 in chronic lymphocytic leukemia (CLL) patients has been known for over two decades, though it's relevance as a therapeutic target in CLL remains understudied.

Experimental Design: We investigated the biological effects and anti-tumor mechanisms engaged by daratumumab in primary CLL cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3412DOI Listing
April 2019
1 Read

Clinical presentation and hematological profile among young and old chronic lymphocytic leukemia patients in Sudan.

BMC Res Notes 2019 Apr 2;12(1):202. Epub 2019 Apr 2.

Department of Hematology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.

Objective: To assess the clinical presentation and hematological profile among young (≤ 55 years) and old (> 55 years) chronic lymphocytic leukemia patients in Sudan.

Result: In the present cross-sectional descriptive study, out of 110 cases studied, among them 31 (28.2%) were young (≤ 55 years) patients with mean age 48 years, and 79 (71. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-019-4239-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446286PMC
April 2019
2 Reads

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

JCI Insight 2019 Apr 2;5. Epub 2019 Apr 2.

Background: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on safety and efficacy of autologous CD19-targeted CAR T-cells for these patients; here we report safety and long-term follow-up of CAR T-cell therapy with or without conditioning chemotherapy for patients with R/R CLL and indolent B-cell non-Hodgkin lymphoma (B-NHL).

Methods: We conducted a phase 1 clinical trial investigating CD19-targeted CAR T-cells incorporating a CD28 costimulatory domain (19-28z). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.122627DOI Listing
April 2019
2 Reads

Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives.

Crit Rev Clin Lab Sci 2019 Apr 2:1-32. Epub 2019 Apr 2.

c Laboratory of Immunology and Immunotherapy , Brest University Medical School Hospital , Brest , France.

Increased resistance to apoptosis represents a key oncogenic mechanism in chronic lymphocytic leukemia (CLL) that has been attributed to the up-regulation of the anti-apoptotic Bcl-2 family members. Such an observation was associated with the development of molecules inhibiting Bcl-2 activity, and among them, BH3-mimetics represent a novel class of therapeutic compounds. In 2016, venetoclax became the first approved oral inhibitor of Bcl-2, and it has been used with success in patients with CLL who present with a 17p deletion or TP53 mutations and in those who have received at least one prior therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10408363.2019.1600468DOI Listing
April 2019
1 Read

Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.

Exp Oncol 2019 Mar;41(1):39-45

Department of Hematology, National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 02000, Ukraine.

Aim: The IGHV mutational status is one of the most important markers for chronic lymphocytic leukemia (CLL) prognostication. Lipoprotein lipase (LPL) gene expression was found to correlate with IGHV status and was suggested as its surrogate marker. Recent data reported that LPL expression might be influenced by pivotal signalling pathways in CLL. Read More

View Article

Download full-text PDF

Source
March 2019
1 Read

NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia.

Oncol Lett 2019 Apr 19;17(4):4016-4023. Epub 2019 Feb 19.

Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah 67148-69914, Iran.

Mutations in certain genes have been suggested to be associated with the pathogenesis of chronic lymphocytic leukemia (CLL), which is the most common leukemia in adults. In a case-control study, 100 patients with CLL and 105 healthy individuals were investigated for Notch homolog 1, translocation-associated () (NOTCH1) c.7544-7545delCT, recombinant splicing factor 3B subunit 1 (SF3B1) c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2019.10048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425375PMC
April 2019
1 Read

Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Target Oncol 2019 Apr;14(2):125-138

Division of Hematology, Department of Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, 455D Wiseman Hall, 410 W 12th Ave, Columbus, OH, 43210, USA.

Inhibitors of Bruton's tyrosine kinase (BTK), a major kinase in the B-cell receptor (BCR) signaling pathway, mediating B-cell proliferation and apoptosis, have substantially altered the management, clinical course, and outcome of patients with B-cell malignancies. This is especially true for patients with previously limited treatment options due to disease characteristics or coexisting diseases. Ibrutinib was the first orally available, nonselective and irreversible inhibitor of BTK approved for the treatment of patients with various B-cell malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-019-00635-7DOI Listing
April 2019
1 Read

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.

Br J Haematol 2019 Mar 28. Epub 2019 Mar 28.

Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Chronic lymphocytic leukaemia (CLL) is a genetically heterogeneous disease characterised by genomic alterations and gene mutations that may portend worse survival or resistance to treatments. A total of 680 blood or bone marrow samples underwent targeted sequencing of 29 genes previously identified as being mutated in CLL, which were correlated to known prognostic clinical characteristics. Overall, 400 (59%) patients were treatment-naïve (TN) and 280 (41%) were relapsed/refractory (R/R). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15877DOI Listing
March 2019
2 Reads
4.711 Impact Factor

Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Haematologica 2019 Mar 28. Epub 2019 Mar 28.

The Ohio State University.

The utility of PET-CT in distinguishing Richter's transformation versus chronic lymphocytic leukemia progression after ibrutinib and/or idelalisib was assessed in a post-hoc analysis of a phase 2 study of venetoclax. Patients underwent PET-CT at screening and were not enrolled/treated if Richter's transformation was confirmed pathologically. Of 167 patients screened, 57 met criteria for biopsy after PET-CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207068DOI Listing
March 2019
1 Read

Activation of Hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia.

Blood 2019 Mar 28. Epub 2019 Mar 28.

Moores Cancer Center, University of California San Diego, La Jolla, CA, United States;

Targeted sequencing of 103 leukemia-associated genes in leukemia cells from 841 treatment-naïve patients with chronic lymphocytic leukemia (CLL) identified 89 (11%) patients have CLL cells with mutations in genes encoding proteins that putatively are involved in Hedgehog (Hh) signaling. Consistent with this, we found that there was a significant association between the presence of these mutations and the expression of GLI1 (Chi square test P < 0.0001), reflecting activation of the Hh pathway. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-09
Publisher Site
http://dx.doi.org/10.1182/blood-2018-09-873695DOI Listing
March 2019
3 Reads

Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.

Ann Hematol 2019 Mar 27. Epub 2019 Mar 27.

School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dąbrowski street 25, 40-032, Katowice, Poland.

In the pathway inhibitor era, the number of allogeneic stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) continues to decrease and this approach should be offered only after careful risk-benefit assessment. Nevertheless, ASCT still remains only curative therapeutic modality for CLL, especially in countries with limited access to novel agents. Thirty patients with CLL at median age of 42 years at diagnosis (range 29-64) underwent ASCT between years 2002 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03679-xDOI Listing
March 2019
1 Read